Copyright © 2011 P. Stiefel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. C. D. Brown, M. Higgins, K. A. Donato et al., “Body mass index and the prevalence of hypertension and dyslipidemia,” Obesity Research, vol. 8, no. 9, pp. 605–619, 2000. View at Scopus
2. K. G. Alberti, P. Zimmet, and J. Shaw, “The metabolic syndrome—a new worldwide definition,” Lancet, vol. 366, no. 9491, pp. 1059–1062, 2005. View at Publisher · View at Google Scholar · View at PubMed
3. D. B. Carr, K. M. Utzschneider, R. L. Hull et al., “Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome,” Diabetes, vol. 53, no. 8, pp. 2087–2094, 2004. View at Publisher · View at Google Scholar · View at Scopus
4. J. G. Neels and J. M. Olefsky, “Inflamed fat: what starts the fire?” Journal of Clinical Investigation, vol. 116, no. 1, pp. 33–35, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
5. S. P. Weisberg, D. Hunter, R. Huber et al., “CCR2 modulates inflammatory and metabolic effects of high-fat feeding,” Journal of Clinical Investigation, vol. 116, no. 1, pp. 115–124, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
6. H. N. Ginsberg, “Insulin resistance and cardiovascular disease,” Journal of Clinical Investigation, vol. 106, no. 4, pp. 453–458, 2000. View at Scopus
7. S. Stas, A. T. Whaley-Connell, and J. R. Sowers, “Aldosterone and hypertension in the cardiometabolic syndrome,” Journal of Clinical Hypertension, vol. 10, no. 2, pp. 94–96, 2008. View at Publisher · View at Google Scholar · View at Scopus
8. S. A. Cooper, A. Whaley-Connell, J. Habibi et al., “Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance,” American Journal of Physiology, vol. 293, no. 4, pp. H2009–H2023, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
9. A. Whaley-Connell, M. S. Johnson, and J. R. Sowers, “Aldosterone: role in the cardiometabolic syndrome and resistant hypertension,” Progress in Cardiovascular Diseases, vol. 52, no. 5, pp. 401–409, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
10. J. S. Williams and G. Williams, “50th anniversary of aldosterone,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 6, pp. 2364–2372, 2003. View at Scopus
11. F. Verrey, “Early aldosterone action: toward filling the gap between transcription and transport,” American Journal of Physiology, vol. 277, no. 3, pp. F319–F327, 1999. View at Scopus
12. A. Bhargava and D. Pearce, “Mechanisms of mineralocorticoid action: determinants of receptor specificity and actions of regulated gene products,” Trends in Endocrinology and Metabolism, vol. 15, no. 4, pp. 147–153, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
13. M. Kellner, A. Peiter, M. Hafner et al., “Early aldosterone up-regulated genes: new pathways for renal disease?” Kidney International, vol. 64, no. 4, pp. 1199–1207, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
14. E. Féraille and A. Doucet, “Sodium-potassium-adenosinetriphosphatase-dependent sodium transport in the kidney: hormonal control,” Physiological Reviews, vol. 81, no. 1, pp. 345–418, 2001. View at Scopus
15. R. F. Reilly and D. H. Ellison, “Mammalian distal tubule: physiology, pathophysiology, and molecular anatomy,” Physiological Reviews, vol. 80, no. 1, pp. 277–313, 2000. View at Scopus
16. N. Farman, S. Boulkroun, and N. Courtois-Coutry, “Sgk: an old enzyme revisited,” Journal of Clinical Investigation, vol. 110, no. 9, pp. 1233–1234, 2002. View at Publisher · View at Google Scholar · View at Scopus
17. H. Garty, M. Lindzen, R. Scanzano et al., “A functional interaction between CHIF and Na-K-ATPase: implication for regulation by FXYD proteins,” American Journal of Physiology, vol. 283, no. 4, pp. F607–F615, 2002. View at Scopus
18. O. G. Muller, R. G. Parnova, G. Centeno, B. C. Rossier, D. Firsov, and J. D. Horisberger, “Mineralocorticoid effects in the kidney: correlation between alphaENaC, GILZ, and Sgk-1 mRNA expression and urinary excretion of Na⁺ and K⁺,” Journal of the American Society of Nephrology, vol. 14, no. 5, pp. 1107–1115, 2003. View at Publisher · View at Google Scholar · View at Scopus
19. S. Boulkroun, M. Fay, M. C. Zennaro et al., “Characterization of rat NDRG2 (N-Myc downstream regulated gene 2), a novel early mineralocorticoid-specific induced gene,” Journal of Biological Chemistry, vol. 277, no. 35, pp. 31506–31515, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
20. M. Wehling, M. Christ, and K. Theisen, “Membrane receptors for aldosterone: a novel pathway for mineralocorticoid action,” American Journal of Physiology, vol. 263, no. 5, pp. E974–E979, 1992. View at Scopus
21. J. W. Funder, “The nongenomic actions of aldosterone,” Endocrine Reviews, vol. 26, no. 3, pp. 313–321, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
22. E. L. Schiffrin, “Effects of aldosterone on the vasculature,” Hypertension, vol. 47, no. 3, pp. 312–318, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
23. J. R. Sowers, “Metabolic risk factors and renal disease,” Kidney International, vol. 71, no. 8, pp. 719–720, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
24. N. J. Brown, “Aldosterone and vascular inflammation,” Hypertension, vol. 51, no. 2, pp. 161–167, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
25. B. M. W. Schmidt, U. Sammer, I. Fleischmann, M. Schlaich, C. Delles, and R. E. Schmieder, “Rapid nongenomic effects of aldosterone on the renal vasculature in humans,” Hypertension, vol. 47, no. 4, pp. 650–655, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
26. T. Y. Chun and J. Howard Pratt, “Nongenomic renal effects of aldosterone: dependency on NO and genomic actions,” Hypertension, vol. 47, no. 4, pp. 636–637, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
27. C. Catena, R. Lapenna, S. Baroselli et al., “Insulin sensitivity in patients with primary aldosteronism: a follow-up study,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 9, pp. 3457–3463, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
28. P. Milliez, X. Girerd, P.-F. Plouin, J. Blacher, M. E. Safar, and J.-J. Mourad, “Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism,” Journal of the American College of Cardiology, vol. 45, no. 8, pp. 1243–1248, 2005. View at Publisher · View at Google Scholar · View at PubMed
29. P. González-Pérez and P. Stiefel, “Increased carotid intima-media thickness in hypertensive patients with a high aldosterone/plasma renin activity ratio and elevated aldosterone plasma concentration,” Journal of Hypertension, vol. 26, no. 7, pp. 1499–1500, 2008. View at Publisher · View at Google Scholar · View at PubMed
30. F. Fallo, F. Veglio, C. Bertello et al., “Prevalence and characteristics of the metabolic syndrome in primary aldosteronism,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 2, pp. 454–459, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
31. F. Fallo, P. Della Mea, N. Sonino et al., “Adiponectin and insulin sensitivity in primary aldosteronism,” American Journal of Hypertension, vol. 20, no. 8, pp. 855–861, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
32. G. Giacchetti, V. Ronconi, F. Turchi et al., “Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study,” Journal of Hypertension, vol. 25, no. 1, pp. 177–186, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
33. G. Colussi, C. Catena, R. Lapenna, E. Nadalini, A. Chiuch, and L. A. Sechi, “Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients,” Diabetes Care, vol. 30, no. 9, pp. 2349–2354, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
34. M. Bochud, J. Nussberger, P. Bovet et al., “Plasma aldosterone is independently associated with the metabolic syndrome,” Hypertension, vol. 48, no. 2, pp. 239–245, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
35. S. Kidambi, J. M. Kotchen, C. E. Grim et al., “Association of adrenal steroids with hypertension and the metabolic syndrome in blacks,” Hypertension, vol. 49, no. 3, pp. 704–711, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
36. J. Matrozova, O. Steichen, L. Amar, S. Zacharieva, X. Jeunemaitre, and P. F. Plouin, “Fasting plasma glucose and serum lipids in patients with primary aldosteronism: a controlled cross-sectional study,” Hypertension, vol. 53, no. 4, pp. 605–610, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
37. B. M. Egan, V. Papademetriou, M. Wofford et al., “Metabolic syndrome and insulin resistance in the TROPHY sub-study: contrasting views in patients with high-normal blood pressure,” American Journal of Hypertension, vol. 18, no. 1, pp. 3–12, 2005. View at Publisher · View at Google Scholar · View at PubMed
38. J. R. Sowers, A. Whaley-Connell, and M. Epstein, “Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension,” Annals of Internal Medicine, vol. 150, no. 11, pp. 776–783, 2009. View at Scopus
39. M. Ehrhart-Bornstein, K. Arakelyan, A. W. Krug, W. A. Scherbaum, and S. R. Bornstein, “Fat cells may be the obesity-hypertension link: human adipogenic factors stimulate aldosterone secretion from adrenocortical cells,” Endocrine Research, vol. 30, no. 4, pp. 865–870, 2004. View at Publisher · View at Google Scholar · View at Scopus
40. D. Kraus, J. Jäger, B. Meier, M. Fasshauer, and J. Klein, “Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes,” Hormone and Metabolic Research, vol. 37, no. 7, pp. 455–459, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
41. D. Petrasek, G. Jensen, M. Tuck, and N. Stern, “In vitro effects of insulin on aldosterone production in rat zona glomerulosa cells,” Life Sciences, vol. 50, no. 23, pp. 1781–1787, 1992. View at Publisher · View at Google Scholar · View at Scopus
42. V. J. Dzau, “Circulating versus local renin-angiotensin system in cardiovascular homeostasis,” Circulation, vol. 77, 1, no. 6, pp. I-4–I-13, 1988. View at Scopus
43. . Min Ae Lee, M. Bohm, M. Paul, and D. Ganten, “Tissue renin-angiotensin systems: their role in cardiovascular disease,” Circulation, vol. 87, 4, no. 5, pp. IV7–IV13, 1993. View at Scopus
44. S. Engeli, R. Negrel, and A. M. Sharma, “Physiology and pathophysiology of the adipose tissue renin-angiotensin system,” Hypertension, vol. 35, no. 6, pp. 1270–1277, 2000.
45. F. Fallo, G. Federspil, F. Veglio, and P. Mulatero, “The metabolic syndrome in primary aldosteronism,” Current Hypertension Reports, vol. 9, no. 2, pp. 106–111, 2007. View at Publisher · View at Google Scholar · View at Scopus
46. R. Sarzani, F. Salvi, P. Dessì-Fulgheri, and A. Rappelli, “Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans,” Journal of Hypertension, vol. 26, no. 5, pp. 831–843, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
47. S. Engeli, K. Gorzelniak, R. Kreutz, N. Runkel, A. Distler, and A. M. Sharma, “Co-expression of renin-angiotensin system genes in human adipose tissue,” Journal of Hypertension, vol. 17, no. 4, pp. 555–560, 1999. View at Publisher · View at Google Scholar · View at Scopus
48. R. Cooper, N. McFarlane-Anderson, F. I. Bennett et al., “ACE, angiotensinogen and obesity: a potential pathway leading to hypertension,” Journal of Human Hypertension, vol. 11, no. 2, pp. 107–111, 1997. View at Scopus
49. D. L. Crandall, H. E. Herzlinger, B. D. Saunders, R. C. Zolotor, L. Feliciano, and P. Cervoni, “Identification and characterization of angiotensin II receptors in rat epididymal adipocyte membranes,” Metabolism, vol. 42, no. 4, pp. 511–515, 1993. View at Publisher · View at Google Scholar · View at Scopus
50. S. Umemura, N. Nyui, K. Tamura et al., “Plasma angiotensinogen concentrations in obese patients,” American Journal of Hypertension, vol. 10, no. 6, pp. 629–633, 1997. View at Publisher · View at Google Scholar · View at Scopus
51. R. H. Eckel, S. M. Grundy, and P. Z. Zimmet, “The metabolic syndrome,” Lancet, vol. 365, no. 9468, pp. 1415–1428, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
52. S. N. Iyer, M. K. Raizada, and M. J. Katovich, “AT1 receptor density changes during development of hypertension in hyperinsulinemic rats,” Clinical and Experimental Hypertension, vol. 18, no. 6, pp. 793–810, 1996. View at Scopus
53. T. L. Goodfriend, D. L. Ball, B. M. Egan, W. B. Campbell, and K. Nithipatikom, “Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion,” Hypertension, vol. 43, no. 2, pp. 358–363, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
54. G. H. Goossens, E. E. Blaak, and M. A. Van Baak, “Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disorders,” Obesity Reviews, vol. 4, no. 1, pp. 43–55, 2003. View at Publisher · View at Google Scholar · View at Scopus
55. S. Engeli, J. Böhnke, K. Gorzelniak et al., “Weight loss and the renin-angiotensin-aldosterone system,” Hypertension, vol. 45, no. 3, pp. 356–362, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
56. J. Redon, R. Cifkova, S. Laurent et al., “Mechanisms of hypertension in the cardiometabolic syndrome,” Journal of Hypertension, vol. 27, no. 3, pp. 441–451, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
57. G. Grassi, R. Dell'Oro, A. Facchini, F. Q. Trevano, G. B. Bolla, and G. Mancia, “Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives,” Journal of Hypertension, vol. 22, no. 12, pp. 2363–2369, 2004. View at Publisher · View at Google Scholar · View at Scopus
58. G. E. Alvarez, S. D. Beske, T. P. Ballard, and K. P. Davy, “Sympathetic neural activation in visceral obesity,” Circulation, vol. 106, no. 20, pp. 2533–2536, 2002. View at Publisher · View at Google Scholar · View at Scopus
59. R. S. Ahima, “Adipose tissue as an endocrine organ,” Obesity, vol. 14, supplement 5, pp. 242S–249S, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
60. A. A. da Silva, J. Carmo, J. Dubinion, and J. E. Hall, “The role of the sympathetic nervous system in obesity-related hypertension,” Current Hypertension Reports, vol. 11, no. 3, pp. 206–211, 2009. View at Publisher · View at Google Scholar · View at Scopus
61. E. P. Gomez-Sanchez, N. Ahmad, D. G. Romero, and C. E. Gomez-Sanchez, “Is aldosterone synthesized within the rat brain?” American Journal of Physiology, vol. 288, no. 2, pp. E342–E346, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
62. A. F. De Nicola, C. Grillo, and S. Gonzalez, “Physiological, biochemical and molecular mechanisms of salt appetite control by mineralocorticoid action in brain,” Brazilian Journal of Medical and Biological Research, vol. 25, no. 12, pp. 1153–1162, 1992. View at Scopus
63. R. B. Felder, “Mineralocorticoid receptors, inflammation and sympathetic drive in a rat model of systolic heart failure,” Experimental Physiology, vol. 95, no. 1, pp. 19–25, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
64. A. C. Kontak, Z. Wang, D. Arbique et al., “Reversible sympathetic overactivity in hypertensive patients with primary aldosteronism,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 10, pp. 4756–4761, 2010. View at Publisher · View at Google Scholar · View at PubMed
65. B. S. Huang, S. Ahmadi, M. Ahmad, R. A. White, and F. H. Leenen, “Central neuronal activation and pressor responses induced by circulating ANG II: role of the brain aldosterone-"ouabain" pathway,” American Journal of Physiology, vol. 299, no. 2, pp. H422–H430, 2010. View at Publisher · View at Google Scholar · View at PubMed
66. B. S. Huang, R. A. White, M. Ahmad, A. Y. Jeng, and F. H. Leenen, “Central infusion of aldosterone synthase inhibitor prevents sympathetic hyperactivity and hypertension by central Na in Wistar rats,” American Journal of Physiology, vol. 295, no. 1, pp. R166–R172, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
67. M. Ehrhart-Bornstein, V. Lamounier-Zepter, A. Schraven et al., “Human adipocytes secrete mineralocorticoid-releasing factors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 2, pp. 14211–14216, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
68. T. W. Kurtz, “New treatment strategies for patients with hypertension and insulin resistance,” American Journal of Medicine, vol. 119, no. 5, supplement 5, pp. S24–S30, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
69. M. Furuhashi, N. Ura, K. Higashiura et al., “Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension,” Hypertension, vol. 42, no. 1, pp. 76–81, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
70. V. Ronconi, F. Turchi, S. Rilli et al., “Metabolic syndrome in primary aldosteronism and essential hypertension: relationship to adiponectin gene variants,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 20, no. 2, pp. 93–100, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
71. C. Guo, V. Ricchiuti, B. Q. Lian et al., “Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines,” Circulation, vol. 117, no. 17, pp. 2253–2261, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
72. V. Lamounier-Zepter and M. Ehrhart-Bornstein, “Fat tissue metabolism and adrenal steroid secretion,” Current Hypertension Reports, vol. 8, no. 1, pp. 30–34, 2006. View at Publisher · View at Google Scholar · View at Scopus
73. M. L. Tuck, J. Sowers, and L. Dornfeld, “The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients,” New England Journal of Medicine, vol. 304, no. 16, pp. 930–933, 1981. View at Scopus
74. R. D. Gordon, M. Stowasser, T. J. Tunny, S. A. Klemm, and J. C. Rutherford, “High incidence of primary aldosteronism in 199 patients referred with hypertension,” Clinical and Experimental Pharmacology and Physiology, vol. 21, no. 4, pp. 315–318, 1994. View at Scopus
75. N. M. Kaplan, “The current epidemic of primary aldosteronism: causes and consequences,” Journal of Hypertension, vol. 22, no. 5, pp. 863–869, 2004. View at Publisher · View at Google Scholar · View at Scopus
76. P. Stiefel, R. Aparicio, J. Carneado, E. Pamies, and J. Villar, “The current epidemic of primary aldosteronism: causes and consequences,” Journal of Hypertension, vol. 22, no. 10, pp. 2040–2042, 2004. View at Scopus
77. P. Stiefel, J. S. García-Morillo, L. Jimenez, et al., “Role of ketoconazole treatment in urinary-free cortisol-to-cortisone and tetrahydrocortisol-to-tetrahydrocortisone ratios in nonectopic Cushing's syndrome,” Endocrine, vol. 18, no. 3, pp. 279–284, 2002. View at Publisher · View at Google Scholar · View at PubMed
78. P. Stiefel and J. Carneado, “Cortisol, aldosterona y diferentes formas de hipertensión: papel de la 11-beta-hidroxiesteroide dehidrogenasa,” Hipertensión, vol. 17, no. 4, pp. 161–168, 2000.
79. J. Gimenez, P. Stiefel, M. L. Miranda et al., “The dispersion quotients: a new approach for evaluating the blood pressure profile in essential versus Cushing's syndrome hypertensive patients,” Annals of the New York Academy of Sciences, vol. 783, pp. 321–323, 1996. View at Publisher · View at Google Scholar · View at Scopus
80. K. K. Gaddam, M. K. Nishizaka, M. N. Pratt-Ubunama et al., “Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion,” Archives of Internal Medicine, vol. 168, no. 11, pp. 1159–1164, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
81. G. E. Callera, R. M. Touyz, R. C. Tostes et al., “Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src,” Hypertension, vol. 45, no. 4, pp. 773–779, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
82. A. Prasad and A. A. Quyyumi, “Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome,” Circulation, vol. 110, no. 11, pp. 1507–1512, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
83. H. Hitomi, H. Kiyomoto, A. Nishiyama et al., “Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells,” Hypertension, vol. 50, no. 4, pp. 750–755, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
84. D. W. Wray and M. A. Supiano, “Impact of aldosterone receptor blockade compared with thiazide therapy on sympathetic nervous system function in geriatric hypertension,” Hypertension, vol. 55, no. 5, pp. 1217–1223, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus